Humoral Risk Factors Associated to Allograft Dysfunction after Lung Transplantation: The Alert of Non-HLA Auto Antibody and HLA-Donor Specific Antibody (DSA) with Non-DSA HLA Antibody

Zhang, A.; Sun, Yuchu; Thomas, Dawn; McCurry, Kenneth R.; Pei, Rui; Budev, Marie

doi:10.1016/j.healun.2021.01.1879

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated pretransplant anti-LG3 antibody and pretransplant HLA-DSA levels were both independently associated with acute vascular rejection ( 13 ). Of note, anti-LG3 antibodies, which are preformed and persist after transplantation, were associated with chronic lung allograft dysfunction in lung transplant recipients ( 80 ). Even if the role of LG3-specific antibodies is increasingly associated with graft failure, the exact underlying mechanisms are still largely unknown.…”

Section: Non-hla Antibody-dependent MVImentioning

confidence: 99%

Microvascular Inflammation of the Renal Allograft: A Reappraisal of the Underlying Mechanisms

et al. 2022

View full text Add to dashboard Cite

Antibody-mediated rejection (ABMR) is associated with poor transplant outcomes and was identified as a leading cause of graft failure after kidney transplantation. Although the hallmark histological features of ABMR (ABMRh), i.e., microvascular inflammation (MVI), usually correlate with the presence of anti-human leukocyte antigen donor-specific antibodies (HLA-DSAs), it is increasingly recognized that kidney transplant recipients can develop ABMRh in the absence of HLA-DSAs. In fact, 40-60% of patients with overt MVI have no circulating HLA-DSAs, suggesting that other mechanisms could be involved. In this review, we provide an update on the current understanding of the different pathogenic processes underpinning MVI. These processes include both antibody-independent and antibody-dependent mechanisms of endothelial injury and ensuing MVI. Specific emphasis is placed on non-HLA antibodies, for which we discuss the ontogeny, putative targets, and mechanisms underlying endothelial toxicity in connection with their clinical impact. A better understanding of these emerging mechanisms of allograft injury and all the effector cells involved in these processes may provide important insights that pave the way for innovative diagnostic tools and highly tailored therapeutic strategies.

show abstract

Section: Non-hla Antibody-dependent MVImentioning

confidence: 99%

Microvascular Inflammation of the Renal Allograft: A Reappraisal of the Underlying Mechanisms

et al. 2022

View full text Add to dashboard Cite

show abstract

“…45 Preformed and persistent antibodies against LG3 were associated with chronic lung allograft dysfunction (CLAD) in lung transplant recipients. 46 Antibodies against agrin were significantly more present in TG patients than in patients with chronic allograft nephropathy (CAN), and their presence was also associated with more rejection episodes. 47…”

Section: Antibodies Against Glomerular Basement Membranementioning

confidence: 99%

“…49 In lung transplantation, anti-PECR antibodies were strongly correlated with CLAD occurrence. 46 Antibodies to Phospholipase A2 Receptor An organ-specific target antigen is phospholipase A2 receptor (Pla2R), a mannose receptor mainly expressed on podocytes and the kidney cortex. 50 The majority of patients with membranous nephropathy (MN), an autoimmune disease, have antibodies against Pla2R.…”

Section: Antibodies To Peroxisomal Trans-2-enoyl-coa Reductasementioning

confidence: 99%

A Comprehensive Overview of the Clinical Relevance and Treatment Options for Antibody-mediated Rejection Associated With Non-HLA Antibodies

Kardol‐Hoefnagel

Otten²

2020

Transplantation

View full text Add to dashboard Cite

Although solid organ transplant results have improved significantly in recent decades, a pivotal cause of impaired long-term outcome is the development of antibody-mediated rejection (AMR), a condition characterized by the presence of donor-specific antibodies to HLA or non-HLA antigens. Highly HLA-sensitized recipients are treated with desensitization protocols to rescue the transplantation. These and other therapies are also applied for the treatment of AMR. Therapeutic protocols include removal of antibodies, depletion of plasma and B cells, inhibition of the complement cascade, and suppression of the T-cell–dependent antibody response. As mounting evidence illustrates the importance of non-HLA antibodies in transplant outcome, there is a need to evaluate the efficacy of treatment protocols on non-HLA antibody levels and graft function. Many reviews have been recently published that provide an overview of the literature describing the association of non-HLA antibodies with rejection in transplantation, whereas an overview of the treatment options for non-HLA AMR is still lacking. In this review, we will therefore provide such an overview. Most reports showed positive effects of non-HLA antibody clearance on graft function. However, monitoring non-HLA antibody levels after treatment along with standardization of therapies is needed to optimally treat solid organ transplant recipients.

show abstract

Humoral Risk Factors Associated to Allograft Dysfunction after Lung Transplantation: The Alert of Non-HLA Auto Antibody and HLA-Donor Specific Antibody (DSA) with Non-DSA HLA Antibody

Cited by 2 publications

References 0 publications

Microvascular Inflammation of the Renal Allograft: A Reappraisal of the Underlying Mechanisms

Microvascular Inflammation of the Renal Allograft: A Reappraisal of the Underlying Mechanisms

A Comprehensive Overview of the Clinical Relevance and Treatment Options for Antibody-mediated Rejection Associated With Non-HLA Antibodies

Contact Info

Product

Resources

About